Chairman of Oracle Corporation strongly promotes AI-driven mRNA vaccines such as Moderna (MRNA.US), and other individual stocks have risen in response.

After Oracle Corporation (ORCL.US) Chairman Larry Ellison emphasized the potential of artificial intelligence (AI) in developing mRNA cancer vaccines, Moderna (MRNA.US) became one of the standout stocks in the US market on Wednesday. Data shows that Moderna closed up 7.27% on Wednesday, at $38.50 per share. At the same time, AI-focused drug developers also saw gains, with AbCellera Biologics (ABCL.US) up 15.36%, Absci (ABSI.US) up 25.16%, Schrodinger (SDGR.US) up 14.11%, Ginkgo Bioworks (DNA.US) up 11.40%, Tempus AI (TEM.US) up 5.90%, and Recursion Pharmaceuticals (RXRX.US) up 8.87%. Larry Ellison stated that AI can be used to develop personalized cancer vaccines based on mRNA and early tumor detection. He explained that AI can be used to analyze tests aimed at identifying tiny tumor fragments circulating in the blood, and personalized cancer vaccines can be developed in approximately two days after gene sequencing of cancerous molecules. He said, "Once we sequence the genes of cancer tumors, you can design a vaccine for each person to inoculate them against this cancer. You can manufacture this mRNA vaccine using artificial intelligence from Siasun Robot & Automation in about 48 hours." Moderna partnered with OpenAI in 2024 and deployed the AI company ChatGPT Enterprise in its operations to accelerate drug development. The personalized cancer vaccine mRNA-4157 being developed in partnership with Merck & Co., Inc. (MRK.US) is currently in late-stage development for skin cancer melanoma patients.